| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6172090 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US5965584 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166043 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US6166042 | TAKEDA PHARMS USA | Pharmaceutical composition |
Jun, 2016
(7 years ago) | |
| US8475841 | TAKEDA PHARMS USA | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6099859 | TAKEDA PHARMS USA | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US6495162 | TAKEDA PHARMS USA | Controlled release oral tablet having a unitary core |
Mar, 2018
(6 years ago) | |
| US7919116 | TAKEDA PHARMS USA | Controlled release metformin formulations |
Mar, 2018
(6 years ago) | |
| US6866866 | TAKEDA PHARMS USA | Controlled release metformin compositions |
Mar, 2021
(3 years ago) | |
| US6790459 | TAKEDA PHARMS USA | Methods for treating diabetes via administration of controlled release metformin |
Mar, 2021
(3 years ago) | |
| US9060941 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(7 months ago) | |
| US8470368 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(7 months ago) | |
| US8668931 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Sep, 2023
(7 months ago) | |
| US7959946 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) | |
| US7785627 | TAKEDA PHARMS USA | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Jul, 2026
(2 years from now) | |
Actoplus Met Xr is owned by Takeda Pharms Usa.
Actoplus Met Xr contains Metformin Hydrochloride; Pioglitazone Hydrochloride.
Actoplus Met Xr has a total of 15 drug patents out of which 13 drug patents have expired.
Expired drug patents of Actoplus Met Xr are:
- US6172090
- US5965584
- US6166043
- US6166042
- US8475841
- US6099859
- US6495162
- US7919116
- US6866866
- US6790459
- US9060941
- US8470368
- US8668931
Actoplus Met Xr was authorised for market use on 12 May, 2009.
Actoplus Met Xr is available in tablet, extended release;oral dosage forms.
Actoplus Met Xr can be used as to reduce gastrointestinal side effects administer with a meal; as starting dose administer once daily with evening meal, adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a pioglitazone and metformin, adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on pioglitazone or metformin alone.
The generics of Actoplus Met Xr are possible to be released after 31 July, 2026.
Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient
Market Authorisation Date: 12 May, 2009
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on piog...
Dosage: TABLET, EXTENDED RELEASE;ORAL
ACTOPLUS MET XR family patents
